Table 5 GRADE evidence profile for impact of NMBA in acute ARDS from systematic review and meta-analysis of randomized controlled trials
No of studies (No of participants) | Quality assessment | Summary of findings | |||||||
|---|---|---|---|---|---|---|---|---|---|
Study limitations | Consistency | Directness | Precision | Publication bias | Relative effect (95% CI) | Best estimate of intervention group | Quality | ||
NMBA vs. Control | |||||||||
ICU Mortality: | |||||||||
3 (431) | Moderate limitations* | No important inconsistency | Direct | Not important imprecision | Unlikely | 0.71 (0.55 – 0.90) | 27% | +++, moderate | |
Mortality at Day 28: | |||||||||
2 (395) | Moderate limitations* | No important inconsistency | Direct | Not important imprecision | Unlikely | 0.68 (0.51 – 0.92) | 23.7% | +++, moderate | |
Barotrauma: | |||||||||
3 (431) | Moderate limitations* | No important inconsistency | Direct | Not important imprecision | Unlikely | 0.45 (0.22 – 0.92) | 0% | +++, moderate | |
Critical illness neuromyopathy: | |||||||||
3 (293) | Moderate limitations* | No important inconsistency | Direct | Not important imprecision | Unlikely | 1.13 (0.76 – 1.67) | 0% | +++, moderate | |